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ABSTRACT 
 In patients with Parkinson’s disease (PD), the restoration of depleted striatal 
dopamine by chronic administration of its precursor, L-DOPA, results in the emergence of 
debilitating involuntary movements.  This complication, termed L-DOPA-induced dyskinesia 
(LID), represents a limitation to the most efficacious treatment for PD motor symptoms.  LID 
progressively increases in severity despite the continual ability of L-DOPA to alleviate 
parkinsonian symptoms, suggesting divergent mechanisms of action and the potential for 
therapeutic intervention.  Utilizing an experimental mouse model of PD, the work presented 
within this thesis investigates the molecular alterations underlying LID.  These studies reveal 
that L-DOPA administration results in pathological intracellular signaling and gene 
expression within striatal medium spiny neurons (MSNs) expressing the dopamine D1 
receptor (D1R).  Following L-DOPA administration, sensitized D1R signaling results in 
hyperactivity of the cyclic 3’-5’ adenosine monophosphate (cAMP)/ cAMP-dependent kinase 
(PKA)/ dopamine- and cAMP-regulated phosphoprotein of 32 kDA (DARPP-32) pathway.  
This exaggerated response results in excessive activation of the downstream extracellular-
regulated kinases 1 and 2 (ERK1/2) and mammalian target of rapamycin complex 1 
(mTORC1) cascades, both of which are implicated in LID.  These data also demonstrate that 
nuclear events mediated by mitogen- and stress-activated kinase 1 (MSK1), a direct ERK1/2 
substrate, promote the induction of the transcription factor ΔFosB, which exacerbates LID.  
Furthermore, the concerted activity of MSK1 and DARPP-32 promotes histone 
H3K27me3S28p and the dissociation from transcription start sites of Rnf2, a Polycomb group 
protein that represses gene expression.  These events are associated with an increase in 
transcription.  Taken together, these studies support the idea that sensitized striatal D1R 
signaling promotes LID by excessive activation of intracellular signaling pathways and 
nuclear events promoting gene expression. 
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INTRODUCTION 
 In general, our everyday movements are so effortless and fluid, imparting us 
with the ability to seamlessly perform even complex actions, that we might take this ability 
for granted.  It provides us with the very things that are necessary for our livelihood – 
essential resources such as food and water, mates for companionship and reproduction, and 
safety from environmental harms – that it would be difficult to image our lives without the 
ability to move.  Furthermore, it imbues us with the notion of free will, and we feel that our 
movements are internally generated and with a conscious purpose.  Consequently, movement 
impairments can alter fundamentally one’s quality of life and sense of independence. 
 
MOVEMENT DISORDERS 
 The central nervous system integrates sensory input and generates motor 
output.  Clinically, its dysfunctions are categorized as either neurological or psychiatric, with 
movement disorders considered neurological.  However, this strict segregation has begun to 
deteriorate with accumulating evidence of psychiatric disturbances experienced by patients 
with neurological disorders and with a re-conceptualization of psychiatric disorders within 
the context of movement1,2.  Attention-deficit/hyperactivity disorder and bipolar disorder are 
considered psychiatric, but their definitions prominently reference movement.  Likewise, 
autism spectrum disorder, obsessive-compulsive disorder and addictive behaviors include 
specific, repeated movements but are viewed as psychiatric.  The conflation of neurology and 
psychiatry in the study of movement disorders is underscored by evidence for shared neural 
substrates, such as the basal ganglia.  Therefore, an understanding of the neurobiology 
underlying movement and its disorders may also provide insight into psychiatric conditions. 
 Movement disorders can be broadly categorized as a reduction of movement, 
termed akinetic-rigid disorders, or as an excess of movement, termed hyperkinetic or 
dyskinetic disorders3.  Idiopathic Parkinson’s disease (PD), an akinetic-rigid disorder, afflicts 
approximately 0.5-3% of the population above the age of 65, increasing in prevalence with 
age4. 
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PARKINSON’S DISEASE 
Clinical Presentation 
 Modern diagnosis of PD relies on the observation of the same motor 
impairments extensively documented in 1817 by the physician James Parkinson5-9.  Present 
early in its prognosis and initially affecting the limbs, the core PD motor symptoms include: 
bradykinesia, a reduced velocity of voluntary movement; hypokinesia, a reduced amplitude 
or poverty of voluntary movements; rigidity, a resistance to passive muscle extension; and 
resting temor.  Additionally, axial motor symptoms, such as postural instability, and gait 
impairments emerge as the disease progresses.  Cognitive, psychiatric and autonomic non-
motor symptoms, including dementia, depression, hallucinations, sleep disorders and 
excessive drooling may appear early in PD or emerge in the later stages of the disease10. 
 
Neuroanatomical and Biochemical Pathology 
 PD symptoms result from an underlying progressive neurodegeneration 
apparent upon post-mortem analysis.  While a variety of similar motor impairments resemble 
those of PD and are collectively referred to as parkinsonism, a diagnosis of PD requires the 
presence of brain protein aggregates, or inclusions, containing α-synuclein11.  These cellular 
inclusions are termed Lewy bodies or Lewy neurites, depending on their localization in the 
cell body or neuronal processes, respectively.  They are believed to progressively ascend 
from the brainstem, radiating out from the basal forebrain and eventually extending 
throughout the cortex in a stereotypical manner12.  Although evidence conflicts concerning 
their pathological or beneficial effect, it is notable that these inclusions exist in nuclei known 
to degenerate in PD.  These nuclei include the substantia nigra par compacta (SNc), the locus 
ceruleus, the nucleus basalis of Meynert and dorsal raphe, affecting the dopaminergic, 
noradrenergic, cholinergic and serotonergic systems, respectively13.   
 In addition to these protein aggregates, the defining pathology of PD is the 
stereotypic degeneration of dopaminergic neurons in the SNc14.  Extensive degeneration 
occurs in its caudolateral regions, progressing medially, dorsally and rostrally with less 
severity15,16.  Histochemical subdivisions within the caudolateral region may show even 
greater susceptibility to degeneration17.  Located within the mesencephalon, these 
degenerating neurons constitute, in part, the mesostriatal pathway, and their death is 
paralleled by a loss of dopaminergic terminals preferentially in the caudal putamen18-20.  
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Consequently, striatal dopamine is diminished in PD patients21-23.  Owing to the buffering 
capability of the mesostriatal pathway, substantial neuronal death, approximately 70% in the 
caudolateral SNc, occurs before motor symptoms appear16.  This degeneration is sufficient to 
produce parkinsonian motor symptoms24,25. 
 
Pharmacotherapy for Motor Symptoms 
 The most efficacious and widely utilized anti-parkinsonian therapy is oral 
administration of the amino acid L-3,4-dihydroxyphenylalanine (L-DOPA), which is 
enzymatically converted to dopamine by aromatic L-amino acid decarboxylase (L-AADC, 
also known as DOPA decarboxylase) to reestablish striatal dopamine content26-30.  
Supplemented with a peripheral L-AADC inhibitor to limit adverse effects by preventing the 
accumulation of dopamine outside of the central nervous system, this combination provides 
acute improvement of PD motor symptoms31,32.  This short-duration effect, lasting a few 
hours, mirrors the synthesis and metabolism of striatal dopamine33-35.  Additionally, chronic 
treatment produces a long-duration effect which lasts approximately one to two 
weeks29,31,36,37.  While L-DOPA continues to alleviate core motor impairments, the later 
emergence of postural instability and non-motor symptoms, both of which are resistant to L-
DOPA therapy, severely reduce one’s quality of life and may be attributed to the 
degeneration of non-dopaminergic neurons7,9,38,39.  Indeed, while L-DOPA affords 
symptomatic relief for a subset of motor deficits, it does not modify the progressive neuronal 
degeneration. 
 
L-DOPA-INDUCED DYSKINESIA 
 While maintaining an antiparkinsonian benefit, prolonged L-DOPA 
administration results in the emergence of a range of undesirable side-effects40.  These may 
include an inability to control one’s impulses, resulting in behaviors such as pathological 
gambling and hypersexuality.  Psychiatric reactions, such as hallucinations or delusions, may 
result.  Additionally, compulsive use of medication despite adverse reactions, such as L-
DOPA induced dyskinesia (LID), may occur.  For most patients, however, the emergence of 
LID represents a major complication and limits the utility of chronic L-DOPA treatment. 
  LID is a drug-induced disorder characterized by excessive movements, which 
can be broadly classified as either choreic or dystonic3,41,42.  Choreic movements are small 
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amplitude, rapid, dance-like movement that appears to randomly flow throughout the body, 
resembling fidgeting in its mild form.  Large amplitude chorea, termed ballism, can also 
occur.  Chorea can co-occur with a writhing and twisting motion, termed choreoathetosis.  
Finally, dystonia is the involuntary contraction of opposing muscles, resulting in the twisting 
of the limbs and abnormal postures.  
 An earlier onset of PD, a longer duration of PD, a longer duration of L-DOPA 
therapy and a higher cumulative amount of L-DOPA are associated to the development of 
LID42.  Taken together, these risk factors suggest that extensive loss of striatal dopamine and 
chronic L-DOPA therapy are both necessary for the development of LID, an idea reinforced 
by the inability of L-DOPA to promote dyskinesia in elderly, non-PD patients43.  Peak-dose 
LID, which parallels blood plasma levels of L-DOPA following its acute administration, is 
dose-dependent when motor symptoms first appear31,36,44-46.  In these early stages, reducing 
the dose of L-DOPA, which continues to maintain an antiparkinsonian effect, minimizes 
peak-dose LID.  Unfortunately, however, the efficacy of this optimal dose is only temporary, 
and the therapeutic range between antiparkinsonian benefits and peak-dose LID narrows over 
time.  While the dose of L-DOPA needed to alleviate PD symptoms remains comparatively 
constant, the threshold for the expression of peak-dose dyskinesia progressively diminishes.  
Ultimately, the two states coincide, reaching a point in which PD patients cannot maintain a 
therapeutic L-DOPA dose without experiencing concomitant dyskinesia47 (Fig. 1). 
 
Figure 1.  Early stages of PD are characterized by sufficient buffering capabilities 
of the remaining dopaminergic system, and the dose of L-DOPA can be adjusted 
for optimal symptomatic benefit without inducing peak-dose LID (left).  However, 
continual dopaminergic loss and unregulated dopamine release result in large 
fluctuations of striatal dopamine, during which peak-dose LID occurs (right).  
Furthermore, the threshold for peak-dose LID coincides with the antiparkinsonian 
threshold, eliminating the possibility for a therapeutic dose without experiencing 
concomitant dyskinesia.  Based on41. 
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 In most cases, LID appears approximately five years after the onset of motor 
symptoms and the consequential initiation of L-DOPA therapy. This delay is attributed to the 
ability of the remaining dopaminergic neurons to release L-DOPA-derived dopamine in a 
regulated, physiological manner41,42.  However, as the progressive degeneration of the 
dopaminergic system continues at the expense of its buffering capabilities, unregulated 
dopamine release produces supraphysiological surges following L-DOPA administration.  
The result is a relatively short therapeutic window during which peak-dose choreic and 
dystonic movements occur, and afterwards striatal dopamine returns to subphysiological 
levels without subsequent L-DOPA administration33-35.  This decline in striatal dopamine 
produces an ‘off’ medication state, a transition termed motor fluctuations, and necessitates 
repeated L-DOPA administration.  Although less common, dyskinesia may be expressed 
while dopamine levels in the brain are rising or falling, a phenomenon termed diphasic 
dyskinesia.  They may also be expressed in an unpredictable manner.  Finally, dyskinesia, 
commonly dystonia, may occur when striatal dopamine returns to subphysiological levels, an 
effect defined as ‘off’ dyskinesia (Fig. 2) 
 
 
Figure 2.  Following L-DOPA administration, peak-dose dyskinesia (left) occurs 
when striatal dopamine is maximal, while diphasic dyskinesia (center) presents 
during its rising or falling phase.  ‘Off’ dystonia (right) occurs during periods of 
diminished striatal dopamine and the reemergence of parkinsonian symptoms.  
Based on48.  
 
CLINICAL MANAGEMENT OF LID 
Once LID emerges, it persists and progressively worsens without therapeutic 
intervention.  Peak-dose LID (herein referred to as LID) can be managed by surgical 
implantation of electrodes, programmed to deliver repetitive stimulation, into the subthalamic 
nuclei (STN).  This procedure, termed deep brain stimulation, can produce a long-term 
improvement in LID for up to five years, an effect attributed to the reduction in the dose of L-
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DOPA required for a therapeutic benefit49.  Although its exact therapeutic mechanisms are 
unknown, it is thought to normalize pathological network activity or to promote movement-
facilitating activity50. 
LID can also be managed by pharmacological means.  Adjunct use of 
amantadine, a N-methyl-D-aspartate (NMDA) receptor antagonist, reduces LID for at least 
one year51-58.  This therapeutic benefit may result from an attenuation of the exaggerated 
NMDA receptor activation in dyskinetic patients during LID59.  Adjunct use of clozapine, 
which has a high affinity for a variety of serotonergic, dopaminergic, muscarinic and 
adrenergic receptors, also reduces LID for at least one year60-65. 
Another approach thought to delay the emergence of LID is to initiate treatment 
with dopamine receptor agonists, thereby minimizing the cumulative exposure to L-DOPA.  
Various agonists with a bias towards the dopamine D2 receptor, such as bromocriptine, 
pramipexol and ropinirole, reduce the severity of dyskinesia; however, these compounds also 
produce less antiparkinsonian benefit, an effect illustrated by the majority of PD patients that 
will eventually require supplemental L-DOPA to manage worsening symptoms6,39,66-71.  
Furthermore, the severity of dyskinesia when agonist-treated patients switch to L-DOPA does 
not differ from those who initiate therapy with L-DOPA72,73.  As a result, a consensus has 
emerged whereby initiating treatment with L-DOPA provides superior initial symptomatic 
relief and confers no long-term harm in developing LID74-78. 
 An emerging concept emphasizes the loss of striatal dopamine and a 
consequential priming of the striatum as a major determinant that, when stimulated by 
dopamine replacement therapy, promotes the development of LID79.  Clinical data directly 
comparing the extent of SNc degeneration while controlling for the duration of L-DOPA 
therapy is impossible to assess, given the ethical considerations of withholding available 
therapy while degeneration persists.  However, indirect evidence supports this hypothesis.  
Severe drug-induced parkinsonism occurring from the selective degeneration of the SNc 
produces a more rapid induction of LID when compared to idiopathic PD25,80.  Therefore, the 
extent of dopaminergic degeneration, rather than the duration of L-DOPA therapy, may 
largely contribute to the development of LID.  This idea is further supported by findings in 
underserved populations with varying stages of PD and where L-DOPA was recently 
introduced.  In these patients, introduction of L-DOPA therapy later in the progression of PD 
led to a more rapid onset of dyskinesia81,82.  These data suggest that the development of LID 
may be particularly influenced by the extent of dopamine loss and the consequential striatal 
priming, whose molecular effects are discussed in more detail later. 
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 LID is expressed when the levels of striatal dopamine, derived from L-DOPA, 
are maximal and is exacerbated by the deteriorating buffering capability of the dopaminergic 
system. In line with these observations, interventions that attenuate the intermittent or 
pulsatile nature of L-DOPA administration is anticipated to reduce LID83.  Pre-clinical 
evidence supports this hypothesis.  Various strategies to establish continuous dopamine 
receptor stimulation, including gene therapy approaches introducing dopamine-synthesizing 
enzymes within the striatum or sustained delivery of L-DOPA, attenuate LID84-88.  These 
approaches also prevent or revert the aberrant gene expression that occurs following pulsatile 
stimulation84,88,89.  Clinical trials using similar strategies are being conducted and may 
represent a future avenue to alleviate LID90-92. 
 
EXPERIMENTAL MODELS OF PD AND LID 
Experimental animal models provide a unique opportunity to investigate PD 
and LID in a more controlled and accessible manner than that afforded by clinical research.  
These models principally utilize 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-
hydroxydopamine (6-OHDA) toxins, whose reuptake and metabolism generate excessive 
oxidative stress to induce cell death93-95.  The result is a selective and permanent lesion of the 
mesostriatal dopaminergic pathway and the emergence of parkinsonian motor symptoms.   
Non-human primates (NHPs) and rodents are commonly used as experimental 
models of PD and LID.  After repeated MPTP intoxication, NHPs mirror the clinical 
presentation and pattern of dopaminergic degeneration observed in PD96.  Following chronic 
L-DOPA treatment, they display similar peak-dose choreoathetoid and dystonic movements 
as those observed in PD patients80,97.  Models utilizing rodents afford a reduced ethical 
dilemma when compared to NHPs.  When stereotaxically injected along the mesostriatal 
pathway, 6-OHDA also selectively and permanently eliminates striatal dopaminergic 
innervation and produces an akinetic state reminiscent of parkinsonian motor impairments98.  
Additionally, repeated administration of L-DOPA results in the appearance of peak-dose 
choreic and dystonic movements, similar to those observed in LID99.   
These models have provided the foundation for the pre-clinical data discussed 
throughout this thesis, and their utility in understanding these conditions and in discovering 
potential therapeutic strategies cannot be understated. They afford biochemical, 
electrophysiology and behavioral analysis in a controlled experimental environment, an 
impossible task with PD patients. The identification of L-DOPA as an anti-parkinsonian 
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therapy was preceded by pre-clinical animal research discovering the neurotransmitters 
present in the brain, their localization, and the behavioral consequences of their depletion and 
reestablishment.  This foundational understanding provided the motivation for ethical and 
hypothesis-driven research utilizing human samples and for experimental therapeutic 
interventions100.  The same argument can made for the discovery and clinical implementation 
of deep brain stimulation (DBS), and both examples serve as guiding principles in the use of 
animal models to investigate LID101.  In the case of the research presented in this thesis, the 
6-OHDA model has provided material for biochemical and behavioral analyses, thereby 
contributing to a body of knowledge guiding ethical and responsible therapeutic 
interventions. 
Whereas the 6-OHDA rodent model reproduces the degeneration of the 
mesostriatal pathway, which is the principle feature of PD, it also has a number of limitations. 
Although the basal ganglia are though to be extensively conserved throughout evolution, the 
likely existence of biochemical and neuroanatomical species-specific differences may 
confound a translation to the human condition102,103. Additionally, the 6-OHDA lesion is 
made unilaterally to create a hemiparkinsonian state, which contrasts with the bilateral 
degeneration observed in PD.  Furthermore, the degeneration occurs more rapidly when 
compared to PD.  A final general observation regards the use of the 6-OHDA lesion model in 
combination with manipulations excising genes from or introducing transgenes into the 
mouse genome. Whereas this approach provides a unique opportunity to probe causal 
relationships, it may result in confounding effects arising from random insertion of the 
transgene within the genome, effects attributable to background strain or compensatory 
effects stemming from constitutive ablation104,105. 
 
THE MESOSTRIATAL DOPAMINE PATHWAY 
 The mesostriatal dopamine pathway is composed of cell bodies residing in the 
mesencephalon whose axons terminate in the dorsal striatum.  Alternatively described as the 
nigrostriatal pathway to reflect the preponderance of neurons in the SNc contributing to this 
innervation, this terminology may represent an oversimplification of a more complex 
distribution of cell bodies throughout the mesencephalon20.  In the context of PD, however, 
the degeneration of dopaminergic neurons in the SNc and their terminals in the striatum 
define its neuropathology106. 
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Anatomy 
 Exemplifying the complexity of the mesostriatal dopaminergic pathway, the 
SNc can be divided into two-tiers: a dorsal tier, which has indistinguishable borders with the 
dopaminergic neurons of both the ventral tegmental area (VTA) and the retrorubral area, and 
a ventral tier, whose cell bodies reside immediately dorsal to or within the substantia nigra 
pars reticulata (SNr)20,107.  The ventral tier projects to biochemically distinct striatal regions, 
termed striosomes, embedded within a surrounding matrix, which receives topographical 
projections from neurons of the dorsal tier.  More medial regions of the dorsal tier 
preferentially innervate the ventral striatum, such as the nucleus accumbens, while more 
lateral regions preferentially innervate the dorsally located putamen, which is reflected in the 
pattern of degeneration in PD.  
 
Synapses and Release 
 During development, mesencephalic dopaminergic neurons project rostrally in 
a large axonal tract, termed the medial forebrain bundle, where they innervate selected striatal 
regions that later develop into striosomes108.  These axonal projections then extend 
throughout the striatum, terminating to form symmetric synapses on dendritic branches and 
the necks of dendritic spines109.  However, approximately 60-70% of these terminals, or 
varicosities, lack an opposing post-synaptic structure, reflecting the diffuse nature of 
dopaminergic signaling110.  Therefore, in contrast to glutamatergic signaling, where high-
fidelity, point-to-point synaptic connections convey neurotransmission, dopaminergic 
signaling appears to have evolved an important spatial component, termed volume 
transmission111. Presumably, this extended ‘sphere of influence’ allows for extensive 
buffering to compensate for the degenerating dopaminergic system and for stable 
symptomatic benefit during initial L-DOPA therapy16,112.  Additionally, dopamine is released 
from the cell body and dendrites of dopaminergic neurons, a process termed somatodendritic 
release, to modulate the surrounding extracellular environment113,114.  Loss of this release 
after neuronal death may lack a similar buffering capability or compensatory mechanism, 
possibly explaining regional differences in the restoration of dopamine levels after L-DOPA 
administration115. 
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The Serotonergic System and LID 
 In the PD brain, L-DOPA-derived dopamine continues to be released into the 
extracellular space despite the progressive degeneration of striatal dopaminergic innervation. 
This release is possible mainly through the serotonergic system116.  This idea is supported by 
PD models in which serotonergic neurons, whose biochemical processes have 
accommodating substrate specificity, are capable of L-DOPA uptake, dopamine synthesis, 
vesicular packaging and axonal release117,118.  In this scenario, the release of dopamine from 
serotonergic terminals is unregulated because of lack of dopamine D2 autoreceptors.  
Accordingly, in dyskinetic PD patients, an agonist of the serotonergic autoreceptor 5-HT1a 
reduces striatal dopamine release and attenuates LID119. 
 
Dopamine Receptors 
 Once released into the extracellular space, dopamine binds to heptahelical 
receptors, or G-protein coupled receptors, which transform this extracellular signal into 
intracellular output.  These receptors are found on the cell body, dendrites and spines of 
MSNs120.  Based on sequence homology and pharmacology, dopamine receptors are broadly 
categorized into two classes: D1-like and D2-like121,122.  D1-like receptors include the 
dopamine D1 and D5 receptors, both of which promote cyclic 3’-5’ adenosine 
monophosphate (cAMP) production by coupling to the G protein subunits Gαs or Gαolf and 
stimulating adenylate cyclase.  The D2-like receptors include the dopamine D2, D3 and D4 
receptors, all of which reduce cAMP synthesis by coupling to either the G protein subunits 
Gαi or Gαo and inhibiting the catalytic activity of adenylate cyclase.  As discussed later, this 
coupling can initiate downstream events to modulate cellular properties. 
 
Regulation of Extracellular Dopamine 
Termination of extracellular striatal dopamine transmission occurs by reuptake 
through the dopamine transporter (DAT) or by enzymatic degradation.  DAT is expressed 
exclusively within dopaminergic neurons, where it is found on unmyelinated axon segments 
or perisynaptic to axon terminals123.  Perisynaptic DAT is situated to regulate dopamine 
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released within the synapse, while DAT located within the axon presumably functions to 
recycle diffuse, extrasynaptic dopamine.   
Two intracellular monoamino oxidase (MAO) isoforms, MAO-A and -B, 
metabolize the majority of striatal dopamine and other catecholamines124.  The striatum is 
enriched in MAO-B and, although primarily expressed in serotonergic neurons, inhibitors of 
this enzyme prolong the antiparkinsonian effects of L-DOPA and minimize motor 
fluctuations32,125,126.  Additionally, MAO-A is present in the striatum, primarily in 
catecholaminergic neurons, and contributes to dopamine metabolism124,126.   
Striatal dopamine is also inactivated by the enzyme catechol-O-
methyltransferase (COMT).  COMT is absent from dopaminergic terminals but is instead 
localized intracellularly or membrane-bound in both glia and medium spiny neurons 
(MSNs)127,128.  However, relative to MAOs, it metabolizes proportionally less dopamine129.  
Despite this reduced influence, COMT inhibitors minimize motor fluctuations, and it 
generates dopamine-derived metabolites associated with LID32,130.  Thus, once dopamine is 
released into the extracellular space, a variety of mechanisms across a diverse number of cell-
types can compensate for the neurodegenerative occurring in PD. 
 
THE BASAL GANGLIA IN PD AND LID 
 Anatomically divided in primates by the axonal tracts of the internal capsule, 
the caudate nucleus and the putamen form the striatum. Because of its extensive 
dopaminergic innervation, the pathological consequences arising from the degeneration of 
this innervation and the motor complications following the prolonged restoration of 
dopamine, the striatum is well suited to be a major neural locus underlying LID.  It is the 
largest in a collection of subcortical nuclei, termed the basal ganglia, whose anatomical 
connectivity creates parallel, or minimally integrating, open- and closed-circuit loops131.  The 
striatum receives glutamatergic afferents from the thalamus and from the entire cerebral 
cortex and sends returning projections principally to the frontal lobe, thereby creating close-
circuit cortical-basal ganglia-cortical loops with these regions.  Depending on their inputs, 
these loops can be broadly categorized as limbic (or emotional), associative (or cognitive) or 
sensorimotor.  Highlighting the segregated nature of these loops, the sensorimotor circuit can 
be sub-categorized into individual ‘channels’ specific for each bodily representation, 
suggesting that similar ‘channels’ may also exists in the limbic and associative loops132.  The 
present discussion focuses on the sensorimotor loop because of the involvement of these 
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cortical regions in the control of motor output via the corticospinal and corticobulbar tracts 
and because the hyperactivation of these cortical areas is associated to LID133.  However, the 
striatal integration of cortical input is thought to be independent of its origin, and analogous 
considerations could possibly be applied to the limbic and associative loops131,134. 
 
The ‘Direct’ and ‘Indirect’ Pathways and the Rate Model 
 The sensorimotor loop originates in cortical regions whose stimulation directly 
results in or is closely associated with motor output.  These areas include the motor, 
premotor, supplementary and cingulate motor cortices, as well as the somatosensory cortex.  
They predominately project to the dorsolateral regions of the posterior putamen and, to a 
lesser extent, to the dorsolateral regions of the caudate nucleus131,132. Additional input to the 
striatum comes from the thalamus, particularly its intralaminar nucleus.  An influential 
working model of the basal ganglia emphasizes two striatal projection pathways with 
opposing influences on motor output135.  According to this model, MSNs constitute striatal 
output and can be segregated into a ‘direct’ or ‘indirect’ pathway, depending on their 
connectivity with basal ganglia output nuclei.  MSNs of the ‘direct’ pathway form synapses 
onto neurons of the internal segment of the globus pallidus (GPi, or entopenducular nucleus 
in rodents), the primary nuclei for the sensorimotor loop, but also the SNr, which together 
create a somatotopically unified structure to form the output nuclei of the basal ganglia.  
Intermingled among neurons of the ‘direct’ pathway, MSNs of the ‘indirect’ pathways, 
however, project to neurons residing in the external segment of the globus pallidus (GPe).  
These neurons, in turn, project to the dorsolateral regions of the subthalamic nucleus (STN).  
Neurons of the STN form synapses onto those of the GPi/SNr, creating an indirect pathway 
of connectivity.  Within the sensorimotor loop, the GPi/SNr projects to the ventral anterior 
and ventral lateral (VA/VL) nuclei of the thalamus, which complete the cortico-basal ganglia-
cortical loop by projecting to motor cortices (Fig. 3).  In addition, the neurons of the GPi/SNr 
also innervate brainstem sensorimotor nuclei, exemplified by projections to the superior 
colliculus to promote saccadic eye movements.  Given the reciprocal superior colliculus-
thalamic projections, this closed-loop may represent a phylogenetically older circuit and a 
fundamental neural unit repurposed in the basal ganglia for cortical input136. 
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Figure 3.  Simplified diagram emphasizing corticostriatal projections and 
unidirectional neurotransmission between basal ganglia nuclei.  Glutamatergic 
projections from the thalamus (not shown) and cortex form synapses onto striatal 
MSNs expressing either D1Rs or D2Rs, which respond to dopamine released by 
neurons of the SNc to modulate MSN activity.  These two populations of MSNs 
have divergent connectivity and opposing effects on motor output.  Based 
on89,135,136 
 
 By integrating excitatory glutamateric input from the cortex and thalamus, 
MSNs of the ‘direct’ and ‘indirect’ pathway provide bidirectional regulation of the GPi/SNr.  
Activity of the ‘direct’ pathway stimulates motor output, while that of the ‘indirect’ pathway 
produces an opposite effect135,137-140.  This difference is attributable to the neurotransmitters 
utilized by their projection neurons141.  The projection neurons of the GPi/SNr tonically 
inhibit those of the thalamus by releasing the amino acid γ-aminobutyric acid (GABA).  The 
thalamus, in turn, sends excitatory glutamatergic projections to motor cortices, ultimately 
generating motor output.  An increase in GPi/SNr activity further suppresses thalamic output 
and, conversely, a decrease in GPi/SNr activity increases thalamic output. GABAergic, 
‘direct’ pathway MSNs inhibit the GPi/SNr to disinhibit, or excite, the thalamus.  Conversely, 
activation of GABAergic, ‘indirect’ pathway MSNs ultimately increase GPi/SNr activity, 
further suppressing thalamic output.  This effect is achieved by inhibiting GABAergic 
neurons of the GPe, which in turn project to the STN.  The net result is a disinhibition of the 
STN, whose excitatory, glutamatergic neurons project to the GPi/SNr.  Increased excitatory 
input to the neurons of the GPi/SNr further suppresses thalamic output.  Therefore, a 
balanced transmission, or rate of activity, between the two feed-forward pathways is 
proposed to generate optimal motor output, while an imbalance between the two is expected 
to generate pathological hypo- or hyper-activity135. 
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Figure 4. The ‘direct’ and ‘indirect’ pathways (left hemisphere) emphasize 
differences in anatomical connectivity and dopamine receptor expression between 
MSNs.  Direct pathway MSNs express D1Rs and form synapses with the basal 
ganglia output nuclei, the GPi/SNr.  Indirect pathway MSNs express D2Rs and 
indirectly influence GPi/SNr activity by intermediate synaptic connections.  
Superimposed upon these intermingled MSNs, striosomes and the surrounding 
matrix (right hemisphere) are enriched for a diverse array of molecules, endowing 
them with a unique biochemistry.  These regions can also vary in their synaptic 
inputs.  Striosomes receive projections from limbic regions, while the matrix is 
innervated by associative and sensorimotor regions.  Striosomes are notable for 
their innervation from the SNc.  Based on142,143 and modified from144. 
 
Striatal dopamine modulates the activity of both ‘direct’ and ‘indirect’ pathway 
MSNs to promote motor output141.  MSNs of the ‘direct’ pathway express the dopamine D1 
receptor (D1R), while those of the ‘indirect’ pathway express the dopamine D2 receptor 
(D2R)89 (Fig. 4).  Their opposing actions on the generation of cAMP are paralleled by their 
effects on MSN excitability.  In general terms, activation of D1Rs facilitates a transition to a 
spike-favorable ‘up-state,’ ultimately decreasing GPi/SNr activity and promoting motor 
output.  Conversely, activation of D2Rs attenuates ‘up-state’ transitions, ultimately 
increasing GPi/SNr output and depressing motor output.  Systemic stimulation with either a 
D1R- or D2R-specific agonist induces motor output, an effect that synergizes following 
striatal dopamine depletion145-147. 
 In the context of this model, the pathologically low levels of striatal dopamine 
in PD promote excessive activation of the ‘indirect’ pathway and attenuate activation of the 
‘direct’ pathway135.  Electrophysiological recordings within the basal ganglia of PD patients 
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before and after dopamine agonist therapy broadly support this model137,148,149.  Stimulation 
of dopamine receptors with apomorphine, an agonist with affinity towards both D1- and D2-
like receptors, suppresses activity in the GPi and STN and increases activity in the GPe, in 
agreement with similar data obtained in NHP PD models150-155.  Furthermore, in PD patients, 
LID is associated with an exaggerated suppression of GPi activity, and experimentally-
induced STN inhibition can evoke choreic and dystonic movements152,156.  
 
The Rate Model: Growing Pains 
 Additional anatomical evidence reveals a more complex interrelationship 
between nuclei of the basal ganglia, with important implications for PD and LID149,157,158.  
For example, ‘direct’ and ‘indirect’ pathway MSNs are not functionally segregated but 
project reciprocating axon collaterals, whose strength is diminished following striatal 
dopamine depletion159.  Furthermore, the ‘hyperdirect’ pathway from motor-related cortices 
to the STN, now redefined as a basal ganglia input nuclei, provides a possible mechanism to 
influence motor output independent from, or in combination with, corticostriatal innervation 
and may underlie the therapeutic effects of DBS within this nuclei50,160.   
 Electrophysiological studies in PD models demonstrate bursting discharge and 
oscillatory activity, suggesting a greater complexity than simply the rate of action 
potentials137,157,158.  Additionally, both ‘direct’ and ‘indirect’ pathways are simultaneously 
active during the initiation of locomotion, suggesting a model in which the patterned activity 
of ‘direct’ pathway activation promotes a specific motor output, while concurrent ‘indirect’ 
pathway activation suppresses competing or incongruent output137,161,162. 
 Although enriched in the striatum, dopamine receptors within the basal ganglia 
are not limited to this nucleus or its MSNs.  They are expressed by all striatal interneurons, 
which have been implicated in PD and LID, and by neurons of the GPe and GPi/SNr, both of 
which receive dopaminergic innervation114,163-165.   
Therefore, while the ‘direct’ and ‘indirect’ pathways of the basal ganglia 
provide a conceptually straightforward explanation to describe the motor output of PD and 
LID, as a model it reflects a simplification of a more complex biology.  In the context of the 
data presented in this thesis, the exaggerated dopaminergic signaling implicated in LID 
predominately occurs in ‘direct’ pathway MSNs, in general agreement with the expected 
hyperactive motor output predicted by this model. 
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The Striosome and Matrix Organization 
 Superimposed upon the ‘direct’ and ‘indirect’ pathways, the dorsal striatum 
contains patch-like regions, termed striosomes, which are endowed with a unique 
biochemistry when compared to the surrounding matrix142,166 (Fig. 4).  MSNs of the ‘direct’ 
and ‘indirect’ pathway are found in both regions.  Striosomes, for example, are enriched in µ-
opioid receptors and the intracellular signaling molecule CalDAG-GEFII.  Although not 
exhaustive, the matrix is enriched in molecules important for acetylcholine transmission, such 
as acetylcholinesterase and choline acetyltransferase, the calcium binding protein calbindin 
D28K and CalDAG-GEFI.  Furthermore, these compartments differ in their afferent and 
efferent projections142,167.  While topographic projections from associative and sensorimotor 
areas innervate the respective medial and lateral regions of the striatal matrix, limbic regions 
provide input to the striosomes168,169.  Striosomes are notable for their projections to the SNc, 
which is thought to regulate dopamine release in the matrix, and for their specific 
dopaminergic innervation by neurons in the ventral tier of the SNc107,170,171.  
 Imbalances in the activity between the two compartments are proposed to 
underlie dopamine-induced behaviors, including LID142,170.  Chronic L-DOPA administration 
results in persistent immediate early gene induction in the striosomes, which absent in the 
ventromedial matrix172,173.  Additionally, striatal dopamine depletion reduces CalDAG-GEFI 
expression in the striatum, an effect that is exacerbated by chronic L-DOPA administration, 
while CalDAG-GEFII is unaffected by the dopamine depletion but is up-regulated in both the 
matrix and striosomes following chronic L-DOPA administration174.  The extent of their 
induction or repression correlates with LID.  Finally, mRNA for the opioid precursor PPE-B 
is enriched in the striosomes of PD patients and NHPs with LID, and a µ-opioid receptor 
antagonist reduces dyskinesia in NHPs175,176.  Taken together, these data suggest that 
excessive imbalance between MSNs of the striosome and matrix may promote LID. 
 
INTRACELLULAR SIGNALING PATHWAYS 
 Because they are enriched in dopamine receptors, represent approximately 90% 
of all striatal neurons and compose striatal output, MSNs are well situated to underlie LID.  
In rodents, a unilateral lesion of the mesostriatal dopaminergic pathway results in 
spontaneous ipsilateral rotations, indicative of their hemi-parkinsonian condition and of an 
imbalance between the striatal outputs of each hemisphere.  However, dopamine receptor 
stimulation, either with apomorphine or L-DOPA administration, produces contralateral 
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rotations. This behavior reflects a now inverted imbalance in striatal output between 
hemispheres and an underlying behavioral sensitization to dopamine receptor stimulation 
developed in response to dopamine depletion177.  Chronic D2-like receptor stimulation 
produces a progressive increase in contralateral rotations and mild dyskinesia; however, 
chronic D1-like receptor stimulation results in a more pronounced increase in contralateral 
rotations and dyskinetic behavior178-180.  These data are supported by a reduction of LID in 
rodent PD models following pre-treatment with D1R-like antagonists, ablation of D1R-
expressing MSNs, or genetic deletion of the D1R 181-185.   
 In NHP PD models, individual stimulation of either the D1R or the D2R is 
sufficient to promote dyskinesia; however, D1R-like stimulation has a greater propensity to 
do so, and D1R-like stimulation induces established dyskinesia to a similar degree as L-
DOPA in PD patients186-188.  Therefore, while both receptors are sufficient to promote 
dyskinesia, synergizing to produce the superior antiparkinsonian and dyskinetic effects of L-
DOPA, D1Rs appear to be prominently involved in the development and manifestation of 
LID.  However, because D1R-like stimulation alleviates PD motor symptoms, its antagonism 
limits the antiparkinsonian effects of L-DOPA189,190.  This dual nature of D1R stimulation 
suggests that divergent downstream mechanisms, one that is antiparkinsonian and another 
that is pro-dyskinetic, occur in the dopamine-depleted striatum. 
 
SPECIFIC AIMS 
 The aim of this thesis is to investigate the molecular events occurring in D1R-
expressing MSNs that promote LID.  In an attempt to achieve this goal, the following studies 
are presented according to their general sequence following D1R stimulation, focusing first 
on the cAMP/PKA/DARPP-32 cascade (PAPER I).  This pathway stimulates ERK1/2 and 
MSK1 to transmit cytoplasmic activity into a nuclear response promoting gene expression 
(PAPER II).  Finally, specific molecular alterations involving repressive Polycomb group 
proteins, which are potentially responsible for induced transcription, are described (PAPER 
III).  
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cAMP/PKA/DARPP-32 pathway (PAPER I) 
 When bound to dopamine, the resulting conformational change of the D1R 
transforms this extracellular stimulus into an intracellular effect by coupling to heterotrimeric 
G proteins, consisting of an α subunit and a β and γ dimer.  Following an exchange of 
guanosine-5'-diphosphate bound to the α subunit for a guanosine-5'-triphosphate, the α 
subunit and β and γ dimer dissociate to stimulate downstream effectors.  In MSNs, the 
dopamine D1R stimulates cAMP production by promoting the dissociation of Gαolf
191-195.  
Release of Gαolf stimulates adenylyl cyclase 5 (AC5), which is highly expressed in the 
striatum, to increase cAMP synthesis196,197.  Accumulating cAMP binds to the regulatory 
subunits of cAMP-dependent protein kinase (PKA), releasing its catalytic subunits to 
phosphorylate downstream substrates198. 
 In PD models, D1R stimulation results in exaggerated downstream effects, 
which contribute to the development of LID.  Increases in D1R surface membrane expression 
or impairments in D1R endocytosis, which can bias intracellular signaling outcomes, are 
associated to LID199-204 (but see 205).  In dyskinetic NHPs, D1R stimulation results in a greater 
amount of Gα bound with guanosine-5'-triphosphate, an effect that correlates with LID
199.  
Striatal dopamine depletion increases the expression of Gαolf, persisting during chronic L-
DOPA administration to also correlate with LID206,207 (but see 208).  This increase is observed 
in the putamen of PD patients209.  Attenuation of Gαolf, however, does not reduce LID, a 
result complicated by evidence that genetic ablation of AC5, which also increases following 
dopamine depletion and persists during L-DOPA administration, or inhibition of PKA reduce 
LID84,206,208,210,211.  Finally, overexpression of G protein-coupled receptor kinase 6, which 
desensitizes D1R-mediated signaling by receptor phosphorylation, suppresses LID212.  Taken 
together, these data reveal that sensitized canonical D1R-mediated signaling underlies the 
development and expression of LID. 
 In support of these data, exaggerated phosphorylation of the PKA substrate, 
dopamine- and cAMP-regulated phosphoprotein of 32 kDA (DARPP-32), is associated with 
LID.  DARPP-32 is enriched in the striatum and integrates intracellular signaling pathways 
within MSNs213.  By acting as a substrate for multiple upstream kinases, individual 
phosphorylation sites of DARPP-32 function to integrate intracellular signaling events, 
ultimately regulating protein phosphatase 1 (PP1).  PKA phosphorylates DARPP-32 on 
threonine 34 (T34), converting DARPP-32 into a potent inhibitor of PP1 and increasing the 
phosphorylation state of downstream PP1 substrates214.  In PD models, L-DOPA 
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administration results in exaggerated PKA-dependent phosphorylation of DARPP-32 at T34 
in D1R-expressing MSNs84,199,206,215-219.  This hypersensitivity is most pronounced after acute 
L-DOPA administration but also persists to a lesser degree following chronic administration.  
Accordingly, global genetic ablation of DARPP-32 or its selective elimination in D1R-
expressing MSNs attenuates LID, further demonstrating an integral role of cAMP signaling 
to promote LID140,215.  
 A similar pathological hyperactivation of the mitogen-activated protein kinases, 
extracellular signal-regulated kinases 1 and 2 (ERK1/2), promote LID215,220.   ERK1/2 are 
found in the nucleus, cytoplasm and dendrites, and they have been implicated in regulating 
activity-dependent gene expression, synaptic plasticity and spine morphology221.  Dual 
phosphorylation of threonine or tyrosine residues in the Thr-Glu-Tyr (TEY) motif of their 
activation loop stimulates ERK1/2 kinase activity222. Like cAMP signaling, this activation is 
more pronounced following acute L-DOPA administration but persists following chronic 
treatment215.  In MSNs of the dopamine-depleted striatum, D1R stimulation promotes 
ERK1/2 activation 181,206,215,216,220,223-230.  Additionally, genetic ablation or pharmacological 
inhibition of upstream cAMP/PKA/DARPP-32 activation reduces ERK1/2 activation and 
attenuates LID84,140,211,215.  Despite this evidence, some studies propose that ERK1/2 
activation in the dopamine-depleted striatum switches from canonical cAMP/PKA/DARPP-
32 activation to an alternative mechanism206,231,232.  
 Furthermore, hyperactivity of the mammalian target of rapamycin complex 1 
(mTORC1) pathway promotes LID220,233,234.  Similar to ERK1/2, mTORC1 promotes cell 
growth and proliferation in mitotic cells and regulates synaptic plasticity in neurons221,235.  
Activation of this pathway is ERK1/2-dependent, but the necessity of upstream PKA-
mediated DARPP-32 phosphorylation is unknown 220.  
 Given the diverse possibility of upstream signaling pathways integrated by the 
mTORC1 pathway, the experiments presented in Paper I were conducted to observe whether 
PKA-mediated DARPP-32 phosphorylation was necessary for ERK1/2 and mTORC1 
activation236. 
 Bitransgenic mice with a unique epitope tag genetically appended to DARPP-
32 expressed under the promoter of either the D1R or D2R allow for its cell-type biochemical 
characterization237.  Following striatal dopamine depletion, chronic L-DOPA administration 
produced an increase in DARPP-32 phosphorylation at T34 selectively in D1R-expressing 
MSNs, but remained unchanged in D2R-expressing MSNs.  These results confirm previous 
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data demonstrating hyperactivity of D1R-mediated signaling and suggest that D2R-mediated 
inhibition of cAMP production does not alter DARPP-32 T34 phosphorylation in this model.  
DARPP-32 can be phosphorylated at threonine 75 (T75) by cyclin-dependent kinase 5, 
converting it to an inhibitor of PKA238.  Inhibition of cyclin-dependent kinase 5, and the 
resulting decrease in T75 phosphorylation, increases PKA-mediated T34 phosphorylation of 
DARPP-32 and other PKA substrates, conceivably explaining the hyperactivity of PKA in 
this model.  As no alterations in phosphorylation at T75 were observed, the increased T34 
phosphorylation is therefore attributable to augmented PKA activity. 
 
Figure 5.  Summary of Paper I.  D1R-mediated stimulation of 
cAMP/PKA/DARPP-32 pathway promotes the activation of downstream ERK1/2 
and mTORC1, resulting in dyskinetic behavior 
  
The DNA-cleaving enzyme cre recombinase excises genomic regions between 
two artificially introduced loxP (flanking loxP or ‘floxed’) sites, ligating the remaining 
DNA239.  When these loxP sites are introduced within a protein-coding region and exogenous 
cre is expressed under the control of a gene promoter, the excision results in ablation of the 
protein product specifically in a genetically defined cell-type.  Using this strategy, mice in 
which DARPP-32 was eliminated in either D1R- or D2R-expressing MSNs were depleted of 
striatal dopamine by a lesion with 6-OHDA and treated chronically with L-DOPA.  
Elimination of DARPP-32 in D1R-, but not D2R-, expressing MSNs attenuated the L-
DOPA-induced phosphorylation of ERK1/2 and a downstream substrate of mTORC1, the 
ribosomal protein S6.  Additionally histone phosphorylation at serine 10 in conjunction with 
acetylation at lysine 14, a post-translational modification generally associated with gene 
induction, was also reduced240.  Furthermore, these effects were reproduced in mice in which 
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the T34 site of DARPP-32 was mutated to an alanine, a residue unable to be phosphorylated 
by PKA, reaffirming the necessity of this kinase and DARPP-32.  Finally, these mice 
displayed reduced LID, a result similarly observed in mice lacking DARPP-32 in D1R-, but 
not D2R-, expressing MSNs or in global DARPP-32 KO140,215.  In sum, these data support 
previous studies demonstrating an essential role for hypersensitized PKA-mediated activity 
and indicate that DARPP-32 stimulates ERK1/2 and mTORC1 signaling pathways 
downstream of the D1R to promote LID. 
 
ERK1/2 and MSK1 pathway (PAPER II) 
 The numerous substrates of ERK1/2 obscure the precise molecular mechanisms 
underlying LID.  Given the progressive development and persistence of LID, its nuclear 
substrates could be hypothesized to transform transient intracellular signaling events into 
more persistent cellular alterations by inducing gene expression241.  ERK1/2 phosphorylation 
of mitogen- and stress-activated kinase 1 (MSK1) at threonine 581 (T581) is necessary to 
stimulate its activity and to promote gene expression concurrent to phosphorylation of 
histones or transcription factors242-245.  Discussed in more detail below, histones efficiently 
structure nuclear DNA and are a platform for regulatory proteins, such as MSK1, to influence 
transcription246.  MSK1 is enriched in the striatum and is expressed by MSNs247.  While the 
closely related MSK2 is also present in the striatum and subserves similar functions to that of 
MSK1, its kinase activity is unaltered by increases in extracellular dopamine resulting from 
cocaine administration248.  In the context of LID, phosphorylation of MSK1 at T581 occurs in 
the same D1R-expressing MSNs as increased ERK1/2 phosphorylation and is dependent on 
this upstream activity181,215,220.  This association, however, has not been demonstrated to 
causally promote LID. 
 In D1R-expressing MSNs, chronic L-DOPA administration induces 
transcription of numerous genes, many of which are closely apposed to regulatory activator 
protein-1 (AP-1) sites249.  AP-1 complexes are heterodimers composed of subunits from the 
Fos and Jun protein families (c-Fos, FosB, Fra1, Fra2 and c-Jun, JunB, JunD, respectively) 
that bind to AP-1 sites250.  In LID models, these AP-1 complexes are predominately 
composed of FosB/ΔFosB and JunD251.  L-DOPA administration induces expression of 
FosB, which can be alternatively spliced to excise two degradation domains, generating the 
truncated and uniquely long-lived transcription factor ΔFosB172,224,252-254.  The protein 
product of this splice variant can persist up to sixteen days after chronic L-DOPA 
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administration, and FosB/ΔFosB mRNA induction continues after one year of chronic L-
DOPA administration254,255.  Within the sensorimotor striatum, FosB/ΔFosB densely 
accumulates in both striosomes and the matrix, but in medioventral regions of the dorsal 
striatum, it is primarily expressed within striosomes172.  In contrast, JunD is constitutively 
expressed and comparatively unaffected by L-DOPA administration, suggesting that 
FosB/ΔFosB are rate-limiting in the formation of AP-1 complexes 253. 
 Indiscriminant striatal overexpression of ΔFosB exacerbates LID256. 
Furthermore, attenuation of FosB/ΔFosB accumulation or overexpression of a truncated JunD 
dominant-negative, which functionally antagonizes AP-1-dependent transcription, reduces 
LID257,258.  Repressed excitability of brain-wide FosB/ΔFosB-expressing neurons reduces 
LID, possibly mediating its effect by also modulating the activity of striatal interneurons or 
neurons outside the striatum, both of which also expressed FosB when challenged with L-
DOPA following chronic administration224,259,260.  Finally, in agreement with pre-clinical 
data, ΔFosB is increased in the striatum of dyskinetic PD patients261. 
 To investigate the involvement of MSK1 in LID, Paper II utilized mice in 
which MSK1 was constitutively ablated or knocked-out (MSK1 KO).  When lesioned with 6-
OHDA and treated chronically with L-DOPA, MSK1 KO mice displayed attenuated 
dyskinetic behavior.  Furthermore, an absence of MSK1 did not impair the antiparkinsonian 
effect of L-DOPA, assessed by the ability of the drug to restore contralateral forelimb use.  
This reduction in LID was not a result of impaired upstream cAMP/PKA/DARPP-32 or 
ERK2 signaling.  However, histone H3 phosphorylation at serine 10 (H3S10p), a previously 
demonstrated MSK1-dependent modification occurring after D1R stimulation, was 
attenuated following L-DOPA administration in MSK1 KO mice248.  Apart from its specific 
co-occurrence with chromatin condensation during mitosis and meiosis, the H3S10p 
modification is commonly associated with gene expression240.  Genetic deletion of MSK1 
resulted in an attenuation of accumulated ΔFosB, which predominately, but not exclusively, 
localized to D1R-expressing MSNs.  Accordingly, chromatin immunoprecipitation (ChIP) of 
the H3S10p modification and subsequent quantification of the precipitated FosB promoter by 
quantitative polymerase chain reaction (ChIP-qPCR) demonstrated that this induction 
occurred at the FosB promoter and was also reduced in MSK1 KO mice.  Although ΔFosB 
accumulated in cells other than D1R-expressing MSNs, its specific overexpression in these 
neurons was sufficient to exacerbate LID.  Conversely, functional antagonism of ΔFosB, 
achieved by overexpression of a truncated cJun dominant-negative, attenuated LID.  Taken 
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together, these data suggest that LID results, in part, from MSK1-mediated FosB/ΔFosB 
induction in D1R-expressing MSNs (Fig. 6). 
 
 
Figure 6.  Summary of Paper II. Concurrent to H3S10p in D1R-expressing MSNs, 
MSK1 stimulates the expression of FosB/ΔFos to promote dyskinetic behavior. 
 
These data provide evidence for nuclear events that underlie LID.   Notable, 
they reflect only subset of possible mechanisms by which ERK1/2 signaling could promote 
LID.  MSK1 represents just one nuclear substrate of ERK1/2, and its elimination produced 
only a mild reduction in LID, an effect not observed in another study262.  Additional nuclear 
substrates, such as the transcription factor Elk1, are also phosphorylated by ERK1/2 and may 
mediate important transcriptional events in concert with or independent from MSK1 
activity241.  However, gene-specific targeting of MSK1 is sufficient to promote transcription 
in cell culture systems 263.  Furthermore, MSK1 can also phosphorylates cAMP-response 
element-binding protein, although immediate early gene induction in the dopamine depleted 
striatum differs from that of the intact striatum in that it appears to be independent of CREB 
activity251.  
 Many of the molecular and behavioral effects of L-DOPA presented in Paper II 
are reminiscent of those following intermittent, elevated striatal dopamine due to chronic 
psychostimulant administration, suggesting a high degree of overlap between these two 
hyperdopaminergic conditions264.  Repeated psychostimulant administration results in 
locomotor sensitization, which is diminished in MSK1 KO mice and exacerbated in the same 
ΔFosB-overexpressing used in this study248,265.  While ΔcJun has no effect on locomotor 
sensitization, it prevents the induction of genes regulated by AP-1 complexes following 
  
24 
psychostimulant administration, emphasizing the mutual involvement of these promoter sites 
in both conditions but also divergent mechanisms between them266. 
  
Polycomb Target Gene Regulation (PAPER III) 
 Biochemical alterations of neuronal histones, or neuroepigenetic modifications, 
can integrate intracellular events to regulate gene expression267.  Two copies of each histone 
protein (H2A, H2B, H3 and H4) create an octamer around which a segment of 147 base pairs 
of DNA wrap themselves to form a nucleosome268.  When repeated across the entire genome 
to form chromatin, nucleosomes provide efficient spatial organization to the extensive 
amount of nuclear DNA.   
 Regulation of gene expression, however, requires efficient compaction of the 
genome but also sufficient physical access necessary for transcription268.  In general terms, 
euchromatin is an ‘open’ chromatin state favorable to transcription, while heterochromatin is 
a ‘closed’ chromatin state, condensed and inaccessible to protein complexes necessary to 
transcription.  Some histone modifications, such as phosphorylation and acetylation, are 
proposed to promote transcription by creating favorable electrostatic interactions and 
increasing accessibility268,269.  Other modifications, such as methylation, do not impart any 
additional charge and may instead serve as binding sites for proteins to regulate the 
expression of accessible genes268.  These modifications generally occur on histone termini, or 
tails, which protrude from the nucleosome core and are accessible to regulatory enzymes270. 
An extensive number of individual modifications exist, and their combinatorial possibilities 
may constitute a ‘histone code’ with predictive effects on chromatin structure and 
transcription270.   
 These modifications can be conceptualized, in simplified terms, by the ‘writers’ 
that induce them, the ‘readers’ that interpret them, and the ‘erasers’ that remove them271.  
Within this framework, MSK1 functions as a ‘writer,’ generating H3S10p.  Additionally, in 
cell culture systems, MSK1/2 transiently phosphorylates serine 28 of histone H3 (H3S28p) 
adjacent to a trimethylated lysine 27 (H3K27me3), generating a combinatorial code 
(H3K27me3S28p), which promotes gene expression272.  During basal conditions, gene 
expression is repressed by the binding of a protein complex composed of Polycomb group 
(PcG) proteins to H3K27me3, thereby acting as a ‘reader’273.  The conventional view posits 
that they exist in two complexes, differing in subunit composition and varying in function.  In 
broad terms, the Polycomb repressive complex 1 (PRC1) binds to the H3K27me3 
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modification catalyzed by PRC2.  Upon the generation of H3K27me3S28p, PcG proteins are 
displaced from the chromatin to facilitate gene induction272.  In cell culture systems, a similar 
mechanism occurs following induction of H3S10p adjacent to H3K9me3, resulting in the 
displacement of heterochromatin protein 1, which normally functions to promote 
heterochromatin formation and gene silencing274-276. 
 PcG proteins are necessary for proper development, where they regulate 
cellular differentiation and maintain cell identity, and their dysfunction has been implicated in 
cancer 277-279.  Their plasticity in terminally differentiated, post-mitotic cells, such as neurons, 
is unknown.  In Paper III, the data presented indicate that PcG genes are derepressed in 
D1R-expressing MSNs upon acute L-DOPA administration, suggesting a greater plasticity of 
PcG-repression than previously known. 
 Acute L-DOPA administration resulted in a prominent increase in global 
H3SK27me3S28p in the dopamine-depleted striatum when compared to the intact striatum, 
and this induction was principally localized to D1R-expressing MSNs.  Repeated L-DOPA 
administration resulted in a progressive decrease in its induction, which failed to completely 
normalize.  Sequencing of striatal RNA (RNA-seq) and ChIP followed by sequencing of 
precipitated genomic regions (ChIP-seq) revealed an association between transcription start 
sites (TSS) marked by H3K27me3S28p and increased mRNA expression.  This association 
was greater than that found for TSS regardless of modifications or for TSS marked by 
H3K27me3 without an adjacent S28p.  These findings are in agreement with similar 
correlations cell culture systems and with the proposal that this modification promotes 
transcription. 
 These genome-wide findings were confirmed by more conventional methods 
for four transcription factors: Atf3, Klf4, Npas4 and Hoxa2.  ChIP-qPCR confirmed the 
presence of H3K27me3 at their TSS in both hemisphere, and a large increase in 
H3K27me3S28p in the dopamine-depleted hemisphere following L-DOPA administration.  
Furthermore, the presence of this combinatorial mark was accompanied by a reduction of 
Rnf2, a component of PRC1, reflecting a dissociation of PcG proteins from chromatin.  The 
expected increase in mRNA resulting from this derepression was confirmed for Atf3, Klf4 
and Npas4, but not for Hoxa2, suggesting that this mechanism functions in conjunction with 
other facilitating factors to influence gene expression.  In support of this idea, the presence of 
trimethylated lysine 4 on histone H3 (H3K4me3), a modification associated with facilitating 
transcription, was observed at the TSS of the three expressed genes but not at that for Hoxa2. 
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 The presence of both the facilitating H3K4me3 and the repressive H3K27me3 
modifications constitutes a bivalent domain, which is proposed to prevent non-specific 
induction and to prime genes for transcription upon appropriate stimuli280.  Interestingly, 
these bivalent domains are plastic and individual modifications can be lost or gained during 
cellular differentiation to influence gene expression280-282.  Although not directly addressed in 
this study, it is tempting to speculate that these exist in mature MSNs and that a similar 
plasticity may occur upon L-DOPA administration. For example, after L-DOPA 
administration, H3K27me3S28p is found at TSS in the dopamine-depleted striatum that are 
not marked by H3K27me3 in the intact striatum, possibly attributable to the induction of both 
a H3K27me3 and H3S28p modification.  Furthermore, after acute L-DOPA administration, a 
subset of genes contained both H3K4me3 and H3K27me3S28p at their TSS, although their 
mRNAs were not induced.  However, the same mRNA were induced by chronic L-DOPA 
administration, perhaps resulting from an exchange of H3K27me3 for a Polycomb-
antagonizing acetylation263.  This influence of transient histone phosphorylation on more 
stable methylation may underlie long-term changes in cellular properties and serve as an 
index of cellular history. 
  
Figure 7.  Summary of Paper III.  Stimulation of the D1R promotes the induction 
of histone H3K27me3S28p by concerted activity of MSK1 and DARPP-32/PP1 
(left).  Concurrent to the presence of this mark is the displacement of Rnf2, a 
component of PRC1, and gene expression (right). 
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In cell culture systems, H3K27me3S28p is induced by MSK1/2272.  Likewise, 
in the dopamine-depleted striatum, this modification was attenuated in MSK1 KO mice, 
confirming this kinase as a ‘writer’ of H3S28p.  However, a greater reduction was observed 
in DARPP-32 T34A mutants, an effect larger than that expected based on its ability to 
attenuate ERK1/2, and therefore MSK1, activation.  The nuclear accumulation of DARPP-32 
promotes H3S10p in response to D1R stimulation, suggesting that a similar mechanism 
might promote the induction of H3K27me3S28p283.  PP1 was capable of H3K27me3S28p 
dephosphorylation in vitro, and inhibition of PP1 in ex vivo striatal tissue was sufficient to 
promote its accumulation.  These data suggest that PP1 acts as an ‘eraser’ of H3S28p and that 
PKA-mediated DARPP-32 phosphorylation, leading to inhibition of PP-1, act in concert with 
MSK1 to generate H3K27me3S28p (Fig. 7). 
 Taken together, the data in Paper III highlight that plasticity of PcG-repressed 
genes in terminally differentiated MSNs may contribute to the development of LID.  They 
also indicate the existence of a dynamic epigenetic landscape that may affect the induction of 
genes following chronic L-DOPA administration. 
 
 
CONCLUSION 
 The data presented within this thesis illustrate some of the molecular 
mechanisms by which L-DOPA administration interacts with sensitized D1Rs to promote 
LID.  These events focus principally on intracellular signaling pathways regulating 
transcription; however, concurrent events implicated in LID also occur in the cytoplasm.  
Hyperactivity of mTORC1, a regulator of protein synthesis, promotes LID220.  This effect 
could result from increased translation of currently present mRNA or translation of newly 
synthesized mRNA following L-DOPA administration.  Additionally, possible alteration in 
the gene expression after chronic L-DOPA administration may result from stable 
neuroepigenetic changes and/or from the accumulation of long-lived transcription factors, 
such as ΔFosB.  These transcriptional regulators may contribute to the basal collection of 
mRNA possibly translated following mTORC1 activation or may promote transcription 
following L-DOPA administration. 
Additional cytoplasmic events result in abnormal corticostriatal transmission.  
Hyperactivity of the cAMP/DARPP-32/PP1 cascade aberrantly modulates glutamatergic 
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input, which may also be exaggerated by the increase in corticostriatal contacts associated 
with LID284.  In LID, this sensitized pathway maintains a persistent potentiation of 
corticostiatal transmission despite de-potentiating stimuli217,285.  This lack of plasticity may 
result in excessive integration or impaired segregation of corticostriatal transmission intended 
for motor learning286.  Specifically, the sensorimotor striatum is necessary for habit formation 
and automatized behavior, which is absent in PD patients287,288.  Interestingly, this form of 
learning is incremental and requires striatal dopaminergic transmission289.  These 
characteristics mirror those of LID, which progresses in severity following L-DOPA 
administration. Therefore, sensitized D1R transmission may result from aberrant plasticity in 
MSNs intended for automatized motor output, potentially explaining the lack of voluntary 
control in LID. 
 Therapeutic interventions to alleviate LID may focus on both perturbed 
transcriptional and translational mechanisms.  Pharmacological approaches targeted to 
epigenetic modifiers are promising therapeutic avenues for cancer could be repurposed for 
LID290.  However, a greater understanding of the neuroepigenetic alterations, if any, is 
warranted.  Additionally, systemic administration of these potential molecules is also likely to 
have unintended consequences on systems outside of select striatal MSNs, and their extended 
use may be limited.  Ultimately, these maladaptive changes are a result of sensitized D1R 
signaling.  Currently, the mechanism(s) behind this phenomenon remain to be fully 
elucidated, although the downstream consequences, such as those presented in this thesis, are 
actively investigated.  It may be that events progressively further downstream of the D1R are 
proportionally less responsible for promoting LID, and interventions intending to prevent 
neurodegeneration or minimize the resulting D1R sensitization may represent additional 
effective therapies. 
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